Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main inclusion criteria:~1. Male and female patients with 18-70 years of age~2. Liver biopsy findings consistent with the diagnosis of NASH with or without compensated cirrhosis within one year before baseline~3. Compensated liver disease~4. Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug~5. All fertile males and females must be using two forms of effective contraception during treatment during the 3 months after treatment.~6. ALT level between 1.3-5 x ULN for 2 occasions during 6 months before screening.~7. HbA1C ≦ 8.0 during screening~Main exclusion criteria:~1. Therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) \*6 months before baseline.~2. History or other evidence of a medical condition associated with chronic liver disease other than NASH (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, \> 20 g/day for female or \> 40 g/day for male, toxin exposures)~3. hepatocellular carcinoma~4. History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease~5. Serum creatinine level \>1.5 times the upper limit of normal at screening and calculated creatinine clearance as calculated by Cockcroft and Gault \< 60mL/min during screening~6. History of ischemic heart disease during screening~7. New York Heart Association (NYHA) Functional Class 1-4 cardiac status during screening~8. Albumin \<3.2g/dL during screening~9. Total bilirubin \>1.2 x ULN during screening. Patients with history of asymptomatic indirect hyperbilirubinemia whose total bilirubin \< 2 x ULN and direct bilirubin \< 20% of total bilirubin could be included.~10. History of prothrombin time \> 15 seconds or International normalized ratio (INR) \> 1.3~11. Organ, stem cell, or bone marrow transplant~12. History of serious concurrent medical illness that in the investigator's opinion might interfere with therapy this includes significant systemic illnesses (other than liver disease) such as chronic pancreatitis~13. Active systemic autoimmune disorder~14. Pregnancy (or lactation) or, in subjects capable of bearing children, inability / unwillingness to practice adequate contraception~15. Females of child-bearing potential (post-puberty) unwilling or unable to have pregnancy testing at any study visit~16. Therapy with a systemic antiviral agent (with the exception of prophylaxis or treatment of influenza or chronic HSV) within the past 30 days prior to screening.~17. Concurrent participation in another clinical trial in which the subject is or will be exposed to another investigational or a non-investigational drug or device within 6 weeks of the screening visit~18. Current therapy with insulin within 1 week prior to screening.~19. Experienced use with PPARg agonist (e.g., rosiglitazone, pioglitazone) within 6 months prior to screening.~20. Known hypersensitivity to any component of PPARg agonists~21. A history of hepatotoxicity to TZDs and/or a history of severe edema or a medically serious fluid-related event associated with the use of TZDs~22. History of metformin use within 3 months prior to screening.~23. Type Ⅰ diabetes~24. Seropositive of HBsAg, anti-HCV or anti-HIV during screening or 3 month prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (Type: EXPERIMENTAL): Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).